Physicians' Academy for Cardiovascular Education

Lipids

The safety of PCSK9 inhibitors - how low can we go?

5' education - Jan. 22, 2020 - Robert Giugliano, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

5' education - Sep. 12, 2019 - Prof. Alberico Catapano

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Growing importance of lowering remnants, also in light of the obesity epidemic

3' education - June 3, 2019 - Børge Nordestgaard

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema - Online CME

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME

Cholesterol guidelines in need of major changes?

5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME

Are very low LDL-c levels safe?

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana - Online CME

The safety of PCSK9 inhibitors - how low can we go?

5' education - Jan. 22, 2020 - Robert Giugliano, MD
Robert Giugliano explains that very low LDL-c is safe, using data of recent clinical trials with LDL-c lowering drugs.

Robert Giugliano explains that very low LDL-c levels are safe, using data of recent clinical trials with LDL-c lowering drugs.

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD
Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD
Thomas Gaziano presents data on worldwide trends in CV mortality and CV risk factors. He gives a brief update on different programs on CVD prevention, both in high and low income countries.

Thomas Gaziano presents data on worldwide trends in CV mortality and CV risk factors. He gives a brief update on different programs on CVD prevention, both in high and low income countries.

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD
Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

New screening tool uses machine learning to identify individuals with probable FH in large datasets

Literature - Dec. 10, 2019 - Myers KD et al., - Lancet Digit Health. 2019

The FIND FH is a machine learning model that identified a large number of individuals with probable FH who had not previously been diagnosed in two distinct types of large medical databases.

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia
A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

AHA 2019 A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

LDL-c target of <70 vs. 100 mg/mL after stroke lowers risk of CV events

News - Nov. 25, 2019

AHA 2019 The Treat Stroke to Target (TST) trial randomized patients with ischemic stroke or TIA with evidence of atherosclerosis to one of two LDL-c targets and found a benefit of the lower target.

APOC3 RNA silencing therapeutic safely lowers triglycerides

News - Nov. 25, 2019

AHA 2019 The siRNA ARO-APOC3 prevents production of APOC3 through RNA interference. It lowered levels of APOC3, TG and VLDL-c and increased HDL-c, and was well tolerated.

RNAi strategy to silence ANGPTL3 safely lowers triglycerides

News - Nov. 18, 2019

AHA 2019 The siRNA ARO-ANG3 directed at ANGPTL3 gave durable lowering of ANGPTL3, TG, VLDL-c, LDL-c and HDL-c up to 16 weeks after a single dose, with a good safety profile.

BET inhibitor therapy did not meet primary endpoint of reducing MACE in post-ACS patients with T2DM

News - Nov. 17, 2019

AHA 2019 The BETonMACE trial evaluating apabetalone did not reduce the primary composite efficacy outcome, nor key secondary outcomes, in T2DM patients with recent ACS and low HDL-c.

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia
The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.

AHA 2019 The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.

Potent and durable LDL-c lowering up to 18 months with siRNA against PCSK9

News - Nov. 16, 2019

AHA 2019 The ORION-10 results showed LDL-c lowering of over 50% with inclisiran, an inhibitor of PCSK9 through RNA interference, with a safety profile similar to placebo.